Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PLX PHARMA INC.

(PLXP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PLx Pharma : VAZALORE™ Now on Shelves; National Media Campaign Launches Today

08/26/2021 | 06:00am EDT

-- Executing broad reach television advertising to support the launch of VAZALORE --

-- Media campaign reach matches extensive distribution at retailers --

SPARTA, N.J., Aug. 26, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules (referred to together as “VAZALORE”), today announced that VAZALORE is now on shelves at major retailers and e-commerce sites nationwide. A national television campaign will also kick-off today and feature spots on high-visibility sports programming as well as popular cable networks.

“We are excited that VAZALORE has hit the shelves nationally and look forward to communicating the benefits of this innovative aspirin therapy to millions of patients at risk for vascular disease,” stated Natasha Giordano, Chief Executive Officer of PLx. “We are confident consumers will recognize VAZALORE as a breakthrough in aspirin delivery, designed to help protect the stomach while providing all of the benefits of aspirin to help prevent another heart attack or clot-related stroke.”

VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, is available in VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count and VAZALORE 325 mg, 30 count.

About VAZALORE

VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. To learn more about VAZALORE, please visit www.vazalore.com.

About PLx Pharma Inc. 

PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.

To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d8d9940c-c2da-487f-b090-acaada2dbcdc


Primary Logo

VAZALORE

PLx Pharma Inc.’s VAZALORE™ Now on Shelves; National Media Campaign Launches Today
Source: PLx Pharma Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about PLX PHARMA INC.
10/14PLX PHARMA : Addresses 'Confusion' Over US Preventive Services Task Force Recommendations ..
MT
10/14PLx Pharma, Inc. Issues Statement on Recent USPTF Recommendations on Aspirin Therapy fo..
GL
10/14PLX PHARMA : Inc. Issues Statement on Recent USPTF Recommendations on Aspirin Therapy for ..
GL
09/21PLX PHARMA : BWS Financial Initiates Coverage on PLx Pharma With Buy Rating, $29 Price Tar..
MT
09/21PLX PHARMA : Corporate Presentation
PU
09/21PLX PHARMA INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
09/20PLX PHARMA INC.(NASDAQCM : PLXP) added to S&P Global BMI Index
CI
09/09PLX PHARMA : to Present at Upcoming Virtual Healthcare Industry Conferences
AQ
08/26PLX PHARMA : Announces Nationwide Rollout of Aspirin Capsules
MT
08/26PLX PHARMA : VAZALORE™ Now on Shelves; National Media Campaign Launches Today
AQ
More news
Analyst Recommendations on PLX PHARMA INC.
More recommendations
Financials (USD)
Sales 2021 9,34 M - -
Net income 2021 -48,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,77x
Yield 2021 -
Capitalization 340 M 340 M -
Capi. / Sales 2021 36,4x
Capi. / Sales 2022 10,4x
Nbr of Employees 10
Free-Float 90,1%
Chart PLX PHARMA INC.
Duration : Period :
PLx Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PLX PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 12,40 $
Average target price 24,00 $
Spread / Average Target 93,5%
EPS Revisions
Managers and Directors
Natasha Giordano President, Chief Executive Officer & Director
Rita M. O'Connor CFO, Head-Manufacturing & Supply Chain
Michael J. Valentino Executive Chairman
Gary S. Balkema Independent Director
Kirk K. Calhoun Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PLX PHARMA INC.124.64%340
JOHNSON & JOHNSON5.32%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
PFIZER, INC.17.22%244 227
ELI LILLY AND COMPANY47.15%225 231